1.14
Okyo Pharma Limited Borsa (OKYO) Ultime notizie
OKYO Pharma achieves key stability milestone for Urcosimod in clinical development - Proactive Investors
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewswire
Small cap wrap: OKYO Pharma, Charbone Hydrogen, Hillcrest... - Proactive financial news
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment - Seeking Alpha
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain - Ophthalmology Times
Urcosimod shows promise in long-term stability test - Investing.com
OKYO Pharma confirms stability of drug candidate By Investing.com - Investing.com South Africa
OKYO Pharma confirms stability of drug candidate - Investing.com India
Urcosimod shows promise in long-term stability test By Investing.com - Investing.com Australia
OKYO Pharma Achieves Key Stability Milestone for Urcosimod - TipRanks
Clinical Trial Breakthrough: New Stability Data Strengthens Urcosimod's Path to FDA Approval - Stock Titan
OKYO Pharma reports long-term shelf stability of corneal pain treatment - Proactive financial news
Dauntless Investment Group, LLC Acquires Significant Stake in OK - GuruFocus
OKYO Pharma (NASDAQ:OKYO) versus IN8bio (NASDAQ:INAB) Head-To-Head Analysis - Defense World
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Growth in Short Interest - Defense World
Okyo Pharma Limited Announces Filing of A Patent Application Covering the Use of Chemerin and Associated Analogues to Treat “Cytokine Storm” Associated with COVID-19 and ARDS - MarketScreener
OKYO Pharma seeks FDA fast track for eye pain treatment By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA Fast Track for eye pain drug By Investing.com - Investing.com Australia
OKYO Pharma seeks FDA fast track for eye pain treatment - Investing.com India
OKYO Pharma seeks FDA Fast Track designation for neuropathic corneal pain treatment - Proactive Investors
OKYO Pharma Seeks FDA Fast Track for Urcosimod in Treating Neuropathic Corneal Pain - TipRanks
OKYO Pharma seeks FDA Fast Track for eye pain drug - Investing.com
OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain - GlobeNewswire
OKYO Pharma secures $1.4 million non-dilutive funding - MSN
Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO) - Defense World
OKYO Pharma advances neuropathic corneal pain drug trial - MSN
OKYO Pharma (NASDAQ:OKYO) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK By Investing.com - Investing.com Australia
H.C. WAINWRIGHT MAINTAINS BUY RATING ON OKYO PHARMA STOCK - Investing.com India
Contrasting OKYO Pharma (NASDAQ:OKYO) and CG Oncology (NASDAQ:CGON) - Defense World
Buy Recommendation for OKYO Pharma Driven by Promising Urcosimod Efficacy and Market Potential - TipRanks
Okyo Pharma's OK-101 renamed urcosimod for eye pain - MSN
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN
OKYO Pharma’s lead asset receives USAN designation "urcosimod By Investing.com - Investing.com Nigeria
OKYO Pharma's lead asset receives USAN designation "urcosimod - MSN
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors UK
Okyo Pharma's OK-101 renamed urcosimod for eye pain By Investing.com - Investing.com South Africa
OKYO Pharma's lead asset receives USAN designation "urcosimod By Investing.com - Investing.com UK
OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod - GlobeNewswire
OKYO Pharma’s Lead Asset OK-101 Receives USAN as Urcosimod - TipRanks
Okyo Pharma Limited Announces OK-101 Officially Assigned USAN : Urcosimod -February 12, 2025 at 07:01 am EST - Marketscreener.com
Revolutionary Eye Drug Urcosimod Targets Two Major Unmet Medical Needs - StockTitan
OKYO Pharma says OK-101 gains USAN reflecting role in ocular disease modulation - Proactive Investors USA
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target By Investing.com - Investing.com South Africa
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):